Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 48
Filtrar
Más filtros

Medicinas Complementárias
Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Pulm Pharmacol Ther ; 56: 86-93, 2019 06.
Artículo en Inglés | MEDLINE | ID: mdl-30917927

RESUMEN

BACKGROUND: There are only limited treatment options for patients with non-cystic fibrosis bronchiectasis (non-CF BE). Human neutrophil elastase (HNE) is a mediator of tissue destruction in non-CF BE. BAY 85-8501, a selective and reversible HNE inhibitor, could represent a new treatment option for this disease. METHODS: This was a phase 2a, randomized, placebo-controlled, double-blind, parallel-group study. The primary objective was to assess the safety and tolerability of 1 mg BAY 85-8501 once daily (OD) for 28 days compared with placebo in patients with non-CF BE. Secondary objectives were to investigate the effects of 4 weeks of treatment with BAY 85-8501 on health-related quality of life, pulmonary function, and inflammatory and tissue damage biomarkers in sputum, blood and/or urine, and to evaluate the pharmacokinetics of BAY 85-8501. RESULTS: Overall, 94 patients (mean age, 66 years; 53% male) were randomized (n = 47 per group), and 82 completed the study (BAY 85-8501, n = 37; placebo, n = 45). Treatment-emergent adverse events (TEAEs) occurred in 31 patients (66%) taking BAY 85-8501 and in 36 patients (77%) taking placebo, and were mostly mild or moderate. The serious TEAEs (BAY 85-8501, n = 3; placebo, n = 1) were not considered to be study-drug related. There were no changes in pulmonary function parameters from baseline to end of treatment, and health-related quality of life did not improve in any group. HNE activity in blood after zymosan challenge decreased significantly with BAY 85-8501 treatment (P = 0.0250 versus placebo). There were no significant differences in other biomarkers between treatment groups, with the exception of a small increase in interleukin-8 levels in sputum in the BAY 85-8501 group. Trough plasma concentrations of BAY 85-8501 plateaued after 2 weeks. CONCLUSIONS: 1 mg BAY 85-8501 OD had a favourable safety and tolerability profile when administered for 28 days to patients with non-CF BE. Further studies with a longer treatment duration are needed to evaluate the potential clinical efficacy in this study population.


Asunto(s)
Bronquiectasia/tratamiento farmacológico , Elastasa de Leucocito/antagonistas & inhibidores , Proteínas Inhibidoras de Proteinasas Secretoras/uso terapéutico , Pirimidinonas/uso terapéutico , Sulfonas/uso terapéutico , Anciano , Bronquiectasia/fisiopatología , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proteínas Inhibidoras de Proteinasas Secretoras/efectos adversos , Proteínas Inhibidoras de Proteinasas Secretoras/farmacocinética , Pirimidinonas/efectos adversos , Pirimidinonas/farmacocinética , Calidad de Vida , Esputo/metabolismo , Sulfonas/efectos adversos , Sulfonas/farmacocinética , Resultado del Tratamiento
2.
Sci Rep ; 9(1): 715, 2019 01 24.
Artículo en Inglés | MEDLINE | ID: mdl-30679470

RESUMEN

Sublingual immunization is emerging as an alternative to nasal immunization and induction of mucosal IgA responses. Using Bacillus anthracis edema toxin (EdTx) as an adjuvant, we previously showed that innate responses triggered after sublingual immunization could limit generation of IgA responses. We tested whether co-administration of a neutrophil elastase inhibitor (NEI) could rescue the ability of EdTx to induce broad antibody responses, including mucosal IgA. NEI supplementation of sublingual vaccines containing EdTx promoted antigen-specific serum IgA responses but also enhanced serum IgG1, and IgG2b responses. This enhancing effect of NEI did not extend to all antibody isotypes and IgG sublclasses, since NEI  reduced serum IgE responses and did not affect IgG2a/c and IgG3 responses. NEI supplementation also promoted anti-Bacillus anthracis protective antigen (PA) neutralizing antibodies and enhanced high affinity IgG1 and IgA antibodies. In addition to serum IgA, NEI supplementation stimulated antigen-specific mucosal IgA responses in the GI tract, and enhanced antigen-specific IgG responses in vaginal washes. Analysis of CD4+ T helper cell responses revealed that co-administration of NEI broadened the profile of cytokine responses, by stimulating Th1, Th2, Th17, and Tfh cytokines. We also noted that NEI had a higher stimulatory effect on IL-5, IL-10, IL-17 responses.


Asunto(s)
Formación de Anticuerpos/inmunología , Antígenos Bacterianos/inmunología , Toxinas Bacterianas/inmunología , Suplementos Dietéticos , Inmunidad Mucosa/inmunología , Membrana Mucosa/inmunología , Proteínas Inhibidoras de Proteinasas Secretoras/administración & dosificación , Vacunas/administración & dosificación , Adyuvantes Inmunológicos , Administración Sublingual , Animales , Antígenos Bacterianos/administración & dosificación , Toxinas Bacterianas/administración & dosificación , Femenino , Inmunoglobulina A/sangre , Inmunoglobulina A/inmunología , Inmunoglobulina E/sangre , Inmunoglobulina E/inmunología , Ratones , Ratones Endogámicos C57BL , Linfocitos T Colaboradores-Inductores , Vacunación
3.
J Nat Prod ; 80(10): 2659-2665, 2017 10 27.
Artículo en Inglés | MEDLINE | ID: mdl-28968119

RESUMEN

As part of an ongoing search for new natural products from medicinal plants to treat respiratory disease, six new compounds, a dihydroflavonol (1) and five C-geranylated flavanones (3, 6, 8, 13, and 14), and 13 known compounds were isolated from mature fruits of Paulownia tomentosa. The structures of the new compounds were determined via interpretation of their spectroscopic data (1D and 2D NMR, UV, IR, ECD, and MS). In biological activity assays with human alveolar basal epithelial cells, the expression of TNF-α-induced proinflammatory cytokines (IL-8 and IL-6) was reduced significantly by the EtOAc fraction of a P. tomentosa extract as well as by the new compounds isolated from this fraction. Furthermore, the majority of the isolates (1-19 except 5-7) were found to inhibit human neutrophil elastase (HNE) activity, with IC50 values ranging from 2.4 ± 1.0 to 74.7 ± 8.5 µM. In kinetic enzymatic assays with the HNE substrate MeOSuc-AAPV-pNA, compound 17 exhibited the highest inhibitory activity (Ki = 3.2 µM) via noncompetitive inhibition. These findings suggest that the flavanone constituents of P. tomentosa fruits may be valuable for the development of new drug candidates to treat airway inflammation.


Asunto(s)
Antiinflamatorios no Esteroideos/aislamiento & purificación , Antiinflamatorios no Esteroideos/farmacología , Flavanonas/aislamiento & purificación , Flavanonas/farmacología , Frutas/química , Magnoliopsida/química , Proteínas Inhibidoras de Proteinasas Secretoras/aislamiento & purificación , Proteínas Inhibidoras de Proteinasas Secretoras/farmacología , Antiinflamatorios no Esteroideos/química , Flavanonas/química , Humanos , Interleucina-6/análisis , Interleucina-8/análisis , Estructura Molecular , Resonancia Magnética Nuclear Biomolecular , Proteínas Inhibidoras de Proteinasas Secretoras/química , República de Corea , Factor de Necrosis Tumoral alfa/análisis , Factor de Necrosis Tumoral alfa/farmacología
4.
Int J Biol Macromol ; 103: 415-423, 2017 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-28528000

RESUMEN

In this study, we have analyzed the structural and functional changes in the nature of Allium sativum Protease Inhibitor (ASPI) on undergoing various denaturation with variable range of pH, temperature and urea (at pH 8.2). ASPI being anti-tryptic in nature has native molecular mass of ∼15kDa. The conformational stability, functional parameters and their correlation were estimated under different conditions using circular dichroism, fluorescence and activity measurements. ASPI was found to fall in belongs to α+ß protein. It demonstrated structural and functional stability in the pH range 5.0-12.0 and up to70°C temperature. Further decrease in pH and increase in temperature induces unfolding followed by aggregation. Chemical induced denaturation was found to be cooperative and transitions were reversible and sigmoid. Tm (midpoint of denaturation), ΔCp (constant pressure heat capacity change) and ΔHm (van't Hoff enthalpy change at Tm were calculated to be 41.25±0.2°C, 1.3±0.07kcalmol-1K-1 and 61±2kcalmol-1 respectively for thermally denatured ASPI earlier. The reversibility of the protein was confirmed for both thermally and chemically denatured ASPI. The results obtained from trypsin inhibitory activity assay and structural studies are found to be in a significant correlation and hence established structure-function relationship of ASPI.


Asunto(s)
Ajo/química , Proteínas de Plantas/química , Proteínas de Plantas/metabolismo , Proteínas Inhibidoras de Proteinasas Secretoras/química , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo , Temperatura , Relación Dosis-Respuesta a Droga , Concentración de Iones de Hidrógeno , Proteínas de Plantas/farmacología , Desnaturalización Proteica/efectos de los fármacos , Estabilidad Proteica , Análisis Espectral , Relación Estructura-Actividad , Inhibidores de Tripsina/química , Inhibidores de Tripsina/metabolismo , Inhibidores de Tripsina/farmacología , Urea/farmacología
5.
Nat Prod Commun ; 12(1): 107-109, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-30549840

RESUMEN

Overexpression of a putative type III polyketide synthase (PKSIII) from the marine myxobacterium Enhygromyxa salina SWB007 in Streptoinyces coelicolor MI 146 led to the accumulation of a novel monoketopiperazine consisting of phenylalanine and isoleucine. This compound was named phileucin and shows high structural similarity to phevalin (aureusimine B). The protease inhibiting activity was tested against human cathepsin L, human leukocyte elastase; bovine trypsin and bovine chymotrypsin. In contrast to phevalin, no protease inhibition was observed.


Asunto(s)
Inhibidores de Proteasas/química , Inhibidores de Proteasas/farmacología , Pirazinas/química , Streptomyces coelicolor/química , Animales , Catepsina L/antagonistas & inhibidores , Catepsina L/biosíntesis , Bovinos , Quimotripsina/antagonistas & inhibidores , Humanos , Espectroscopía de Resonancia Magnética , Myxococcales/enzimología , Sintasas Poliquetidas/metabolismo , Proteínas Inhibidoras de Proteinasas Secretoras/química , Proteínas Inhibidoras de Proteinasas Secretoras/farmacología , Espectrometría de Masa por Ionización de Electrospray , Espectrofotometría Infrarroja , Espectrofotometría Ultravioleta , Inhibidores de Tripsina/química , Inhibidores de Tripsina/farmacología
6.
Nat Prod Commun ; 10(1): 167-70, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25920241

RESUMEN

Neutrophile elastase has the capacity to degrade elastin, a protein found in the connective tissue of the lungs. Unchecked elastase leads to pulmonary pathologies. Therefore, the development of elastase inhibitors is currently actively pursued in the therapeutic field. Several triterpenoids have been reported as inhibitors against elastase or its release. Such compounds could be valuable for the design of new drugs. This review is aimed at giving a comprehensive insight into the recent work performed in the field of triterpenoid-induced elastase inhibition.


Asunto(s)
Proteínas Inhibidoras de Proteinasas Secretoras/química , Triterpenos/química
9.
Science ; 343(6170): 552-5, 2014 Jan 31.
Artículo en Inglés | MEDLINE | ID: mdl-24482481

RESUMEN

Accelerated gene evolution is a hallmark of pathogen adaptation following a host jump. Here, we describe the biochemical basis of adaptation and specialization of a plant pathogen effector after its colonization of a new host. Orthologous protease inhibitor effectors from the Irish potato famine pathogen, Phytophthora infestans, and its sister species, Phytophthora mirabilis, which is responsible for infection of Mirabilis jalapa, are adapted to protease targets unique to their respective host plants. Amino acid polymorphisms in both the inhibitors and their target proteases underpin this biochemical specialization. Our results link effector specialization to diversification and speciation of this plant pathogen.


Asunto(s)
Mirabilis/enzimología , Mirabilis/microbiología , Phytophthora infestans/patogenicidad , Enfermedades de las Plantas/microbiología , Proteínas de Plantas/metabolismo , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo , Solanum tuberosum/enzimología , Solanum tuberosum/microbiología , Secuencia de Aminoácidos/genética , Sustitución de Aminoácidos/genética , Evolución Molecular , Filogenia , Phytophthora infestans/genética , Proteínas de Plantas/clasificación , Proteínas de Plantas/genética , Polimorfismo Genético , Proteínas Inhibidoras de Proteinasas Secretoras/clasificación , Proteínas Inhibidoras de Proteinasas Secretoras/genética , Especificidad de la Especie
10.
Curr Opin Hematol ; 21(1): 23-8, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24241342

RESUMEN

PURPOSE OF REVIEW: Therapeutic inhibition of neutrophil-derived elastases holds promise with powerful treatment effects observed in various preclinical models of lung, bowel and skin inflammation and ischaemia-reperfusion injury relevant to myocardial infarction, stroke and transplant medicine. RECENT FINDINGS: This brief review considers recent studies eliciting the complex interaction between neutrophil-derived elastases and endogenous inhibitors that determines elastase-mediated inflammation in humans. Translating results of preclinical studies with neutrophil elastase inhibitors remains challenging. Future clinical studies will harness developments in drug delivery and utilize more specific markers of neutrophil elastase activity to inform on the efficacy of inhibition. A summary of recently published and ongoing clinical trials with synthetic inhibitors sivelestat and AZD9668 and recombinant elafin is provided. SUMMARY: Clinical trials with neutrophil elastase inhibitors in lung and cardiovascular disease are ongoing, and future studies will incorporate novel delivery approaches and be directed by specific markers of neutrophil-derived elastase activity to target inhibition to the sites of inflammatory tissue injury.


Asunto(s)
Antiinflamatorios/uso terapéutico , Inflamación/tratamiento farmacológico , Elastasa de Leucocito/antagonistas & inhibidores , Proteínas Inhibidoras de Proteinasas Secretoras/uso terapéutico , Daño por Reperfusión/tratamiento farmacológico , Ensayos Clínicos como Asunto , Evaluación Preclínica de Medicamentos , Humanos
11.
Masui ; 62(5): 541-6, 2013 May.
Artículo en Japonés | MEDLINE | ID: mdl-23772527

RESUMEN

Acute respiratory distress syndrome (ARDS) is a noncardiogenic pulmonary edema resulting from increased capillary permeability. Numerous pharmacologic therapies have been studied for prevention and treatment of ARDS. Although several pharmacological therapies could improve patient's respiratory function, there have been no controlled studies which clearly demonstrated the clinical benefit for ARDS-related mortality. The role of corticosteroids in ARDS remains controversial. Available evidence is against early administration of high-dose corticosteroids (methylprednisolon 120 mg x kg-1 x day - 1). In contrast, low-dose corticosteroid therapy (methylprednisolon 0.5-2.5mgg kg-1 xday-1)remains controversial. With regard to sivelestat sodium, a specific inhibitor of neutrophil elastase, although the effectiveness in decreasing mortality was not clarified, increases in lung oxygenation and ventilator-free days have consistently been revealed. Other probable pharmacologic therapies for ARDS include continuous infusion of cisatracurium. In conclusion, there are not established drugs for ARDS, and further studies are necessary to reveal the clinical effectiveness of the above mentioned and novel pharmacologic therapies.


Asunto(s)
Anticoagulantes/administración & dosificación , Glicina/análogos & derivados , Metilprednisolona/administración & dosificación , Proteínas Inhibidoras de Proteinasas Secretoras/administración & dosificación , Síndrome de Dificultad Respiratoria/tratamiento farmacológico , Sulfonamidas/administración & dosificación , Animales , Atracurio/administración & dosificación , Atracurio/análogos & derivados , Coagulación Intravascular Diseminada/complicaciones , Coagulación Intravascular Diseminada/tratamiento farmacológico , Glicina/administración & dosificación , Humanos , Metaanálisis como Asunto , Metilprednisolona/efectos adversos , Bloqueantes Neuromusculares/administración & dosificación , Proteína C/administración & dosificación , Quimioterapia por Pulso , Ensayos Clínicos Controlados Aleatorios como Asunto , Proteínas Recombinantes/administración & dosificación , Síndrome de Dificultad Respiratoria/complicaciones
12.
Inflammation ; 36(6): 1348-56, 2013 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23794035

RESUMEN

In the present study, we investigated the protective effects of sivelestat on acute pancreatitis (AP) in a rat model. Sivelestat is a specific neutrophil elastase inhibitor, which has been developed in Japan in 1991. Varying doses of sivelestat in normal saline were infused continuously in sivelestat-treated groups through osmotic pumps. Blood and pancreas samples were collected for serological and histopathological studies, and ten rats in each group were taken for survival observation. Increasing doses of sivelestat inhibits the expression of lipase, amylase, corticosterone, IL-1ß, TNF-α, and nuclear factor-κB. Furthermore, sivelestat reduces the inflammatory cells infiltration, histological damage, and mortality rate. Meanwhile, the total antioxidant power and serum level of IL-4 in high-dose sivelestat-treated groups were increased. Our findings suggest that the increasing doses of sivelestat protect against caerulein-induced AP in rats, and this protection is possibly associated with the anti-inflammatory ability of sivelestat.


Asunto(s)
Glicina/análogos & derivados , Estrés Oxidativo/efectos de los fármacos , Pancreatitis Aguda Necrotizante/tratamiento farmacológico , Inhibidores de Serina Proteinasa/uso terapéutico , Sulfonamidas/uso terapéutico , Amilasas/biosíntesis , Animales , Antioxidantes/uso terapéutico , Ceruletida , Corticosterona/biosíntesis , Modelos Animales de Enfermedad , Glicina/uso terapéutico , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Interleucina-1beta/biosíntesis , Interleucina-4/sangre , Lipasa/biosíntesis , Masculino , Páncreas/metabolismo , Pancreatitis Aguda Necrotizante/inducido químicamente , Pancreatitis Aguda Necrotizante/mortalidad , Proteínas Inhibidoras de Proteinasas Secretoras/uso terapéutico , Ratas , Ratas Sprague-Dawley , Sobrevida , Factor de Transcripción ReIA/biosíntesis , Factor de Necrosis Tumoral alfa/biosíntesis
13.
Prikl Biokhim Mikrobiol ; 49(1): 34-40, 2013.
Artículo en Ruso | MEDLINE | ID: mdl-23662448

RESUMEN

The PKPIJ-B gene encoding a chymotrypsin inhibitor from a subfamily of potato Kunitz-type proteinase inhibitors (PKPI) in potatoes (Solanum tuberosum L. cv. Yubilei Zhukova) was cloned into a pET23a vector and then expressed in Escherichia coli. The recombinant PKPIJ-B protein obtained in the inclusion bodies was denatured, purified by high-performance liquid chromatography (HPLC) on Mono Q under denaturing conditions, and renaturated. The renaturated protein was additionally purified using HPLC on DEAE-ToyoPearl. The PKPIJ-B protein efficiently suppressed chymotrypsin activity, had a weaker effect on trypsin, and inhibited the growth and development of phytopathogenic microorganisms affecting potato plants.


Asunto(s)
Expresión Génica , Proteínas de Plantas , Proteínas Inhibidoras de Proteinasas Secretoras , Solanum tuberosum/química , Escherichia coli/genética , Escherichia coli/crecimiento & desarrollo , Escherichia coli/metabolismo , Proteínas de Plantas/biosíntesis , Proteínas de Plantas/química , Proteínas de Plantas/genética , Proteínas de Plantas/aislamiento & purificación , Proteínas Inhibidoras de Proteinasas Secretoras/biosíntesis , Proteínas Inhibidoras de Proteinasas Secretoras/química , Proteínas Inhibidoras de Proteinasas Secretoras/genética , Proteínas Inhibidoras de Proteinasas Secretoras/aislamiento & purificación , Solanum tuberosum/genética
14.
Cell Transplant ; 22(1): 159-73, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-22472201

RESUMEN

Although islet transplantation can achieve insulin independence in patients with type 1 diabetes, sufficient number of islets derived from two or more donors is usually required to achieve normoglycemia. Activated neutrophils and neutrophil elastase (NE), which is released from these neutrophils, can directly cause injury in islet grafts. We hypothesized that inhibition of NE improves islet isolation and islet allograft survival. We tested our hypothesis by examining the effects of modified ET-Kyoto solution supplemented with sivelestat, a NE inhibitor (S-Kyoto solution), on islet yield and viability in islet isolation and the effect of intraperitoneally injected sivelestat on islet graft survival in a mouse allotransplant model. NE and proinflammatory cytokines such as tumor necrosis factor (TNF)-α and interleukin (IL)-6 increased markedly at the end of warm digestion during islet isolation and exhibited direct cytotoxic activity against the islets causing their apoptosis. The use of S-Kyoto solution significantly improved islet yield and viability. Furthermore, treatment with sivelestat resulted in significant prolongation of islet allograft survival in recipient mice. Furthermore, serum levels of IL-6 and TNF-α at 1 and 2 weeks posttransplantation were significantly higher in islet recipients than before transplantation. Our results indicated that NE released from activated neutrophils negatively affects islet survival and that its suppression both in vitro and in vivo improved islet yield and prolonged islet graft survival. The results suggest that inhibition of NE activity could be potentially useful in islet transplantation for patients with type 1 diabetes mellitus.


Asunto(s)
Trasplante de Islotes Pancreáticos/métodos , Islotes Pancreáticos/citología , Islotes Pancreáticos/efectos de los fármacos , Proteínas Inhibidoras de Proteinasas Secretoras/farmacología , Acetilcisteína/farmacología , Animales , Apoptosis/efectos de los fármacos , Bucladesina/farmacología , Supervivencia Celular/efectos de los fármacos , Supervivencia Celular/fisiología , Gluconatos/farmacología , Derivados de Hidroxietil Almidón/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Nitroglicerina/farmacología , Distribución Aleatoria , Trehalosa/farmacología
15.
Exp Dermatol ; 22(1): 30-5, 2013 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-23173934

RESUMEN

There is mounting evidence that Th2 cytokines adversely affect skin barrier functions and contribute to the pathogenesis of atopic dermatitis (AD). AD is also characterized by abnormal cohesion in the stratum corneum (SC). However, the contribution of Th2 cytokines to this abnormality remains unknown. This study examined the effects of IL-4, a prototypic Th2 cytokine, on the cohesion of the SC. Structural and physiological assessments revealed that repeated intradermal injections of IL-4 compromised the cohesion of the SC of normal hairless mice. Two potential mechanisms were explored to account for the altered cohesion. First, IL-4 decreased the amount of corneodesmosomes and down-regulated the expression of desmoglein 1, but not of corneodesmosin (CDSN) or loricrin expression, in murine skin and in cultured human keratinocytes (KC). IL-4 did not affect the skin surface pH, and in situ zymography revealed no net change in total serine protease activity in the IL-4-treated SC. Yet, IL-4 enhanced expression of kallikrein (KLK)7, while simultaneously down-regulating KLK5 and KLK14. Finally, IL-4 did not alter the expression of the lympho-epithelial Kazal-type inhibitor (LEKTI) in KC. This study suggests that IL-4 abrogates the cohesion of SC primarily by reducing epidermal differentiation.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Dermatitis Atópica/etiología , Epidermis/efectos de los fármacos , Epidermis/metabolismo , Interleucina-4/farmacología , Queratinocitos/efectos de los fármacos , Animales , Calcio/farmacología , Diferenciación Celular/efectos de los fármacos , Células Cultivadas , Desmogleína 1/metabolismo , Epidermis/ultraestructura , Femenino , Glicoproteínas/metabolismo , Humanos , Péptidos y Proteínas de Señalización Intercelular , Calicreínas/metabolismo , Queratinocitos/metabolismo , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos C57BL , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo , ARN Mensajero/metabolismo , Inhibidor de Serinpeptidasas Tipo Kazal-5 , Serina Proteasas/metabolismo
16.
Plant Physiol Biochem ; 60: 59-66, 2012 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22902798

RESUMEN

During plant-pathogen interaction, oomycetes secrete effectors into the plant apoplast where they interact with host resistance proteins, which are accumulated after wounding or infection. Previous studies showed that the expression profile of pathogenesis related proteins is proportional to the resistance of different cultivars toward Phytophthora infestans infection. The aim of this work was to analyze the expression pattern of apoplastic hydrophobic proteins (AHPs), after 24 h of wounding or infection, in tubers from two potato cultivars with different resistance to P. infestans, Spunta (susceptible) and Innovator (resistant). Intercellular washing fluid (IWF) was extracted from tubers and chromatographed into a PepRPC™ HR5-5 column in FPLC eluted with a linear gradient of 75% acetonitrile. Then, AHPs were analyzed by SDS-PAGE and identified by MALDI-TOF-MS. Innovator cv. showed a higher basal AHP content compared to Spunta cv. In the latter, infection induced accumulation of patatins and protease inhibitors (PIs), whereas in Innovator cv. no changes in PIs accumulation were observed. In response to P. infestans infection, lipoxygenase, enolase, annexin p34 and glutarredoxin/cyclophilin were accumulated in both cultivars. These results suggest that the AHPs content may be related to the protection against the oomycete and with the degree of potato resistance to pathogens. Additionally, a considerable number of the proteins putatively identified lacked the signal peptide and, being SecretomeP positive, suggest unconventional protein secretion.


Asunto(s)
Phytophthora infestans/patogenicidad , Enfermedades de las Plantas/inmunología , Proteínas de Plantas/metabolismo , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo , Solanum tuberosum/metabolismo , Resistencia a la Enfermedad , Electroforesis en Gel de Poliacrilamida , Regulación de la Expresión Génica de las Plantas , Interacciones Huésped-Patógeno , Interacciones Hidrofóbicas e Hidrofílicas , Enfermedades de las Plantas/parasitología , Proteínas de Plantas/análisis , Proteínas de Plantas/aislamiento & purificación , Tubérculos de la Planta/inmunología , Tubérculos de la Planta/metabolismo , Tubérculos de la Planta/parasitología , Proteínas Inhibidoras de Proteinasas Secretoras/análisis , Proteómica , Solanum tuberosum/inmunología , Solanum tuberosum/parasitología , Solanum tuberosum/fisiología , Espectrometría de Masa por Láser de Matriz Asistida de Ionización Desorción , Heridas y Lesiones
17.
Nat Prod Commun ; 7(12): 1623-6, 2012 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-23413568

RESUMEN

Through bioassay-guided fractionation, thirteen compounds (1-13) were isolated from the dry root of Semiaquilegia adoxoides, known as Tiankuizi in traditional Chinese medicine (TCM). Among these, four benzoic acid derivatives (1, 2, 4, 5), one 4,6-dimethoxy-5-methyl-2H-pyran-2-one (10) and one 1,2,3-propanetriol (13) were found for the first time in S. adoxoides. This is the first record of compound 10 from a natural source. 4-Hydroxybenzoic acid (1) and 3,4-dihyroxybenzoic acid (2) showed selective inhibition against elastase release and superoxide anion generation, with IC50 values of 3.20 and 6.21 microg/mL, respectively. Compound 1 had 7-fold better activity than the positive control against elastase release induced by human neutrophils. Overall, our studies demonstrated Tiankuizi (S. adoxoides) as a potential TCM and isolates 1 and 2 as promising lead compounds for neutrophilic inflammatory diseases.


Asunto(s)
Antiinflamatorios no Esteroideos/farmacología , Benzoatos/farmacología , Infiltración Neutrófila/efectos de los fármacos , Semiaquilegia/química , Antineoplásicos Fitogénicos/farmacología , Antioxidantes/química , Antioxidantes/farmacología , Bioensayo , Supervivencia Celular , Ensayos de Selección de Medicamentos Antitumorales , Humanos , Técnicas In Vitro , Indicadores y Reactivos , Espectroscopía de Resonancia Magnética , Medicina Tradicional China , Extractos Vegetales/química , Raíces de Plantas/química , Proteínas Inhibidoras de Proteinasas Secretoras/química , Proteínas Inhibidoras de Proteinasas Secretoras/farmacología , Superóxidos/química
18.
Exp Dermatol ; 20(11): 905-10, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-21899598

RESUMEN

A balanced proteolytic activity in the epidermis is vital to maintain epidermal homoeostasis and barrier function. Distinct protease-inhibitor systems are operating in different epidermal layers. In the uppermost layer, the stratum corneum, kallikrein-like proteases and their inhibitors are responsible for desquamation of the cornified keratinocytes, thus regulating the integrity of the epidermal barrier. Following discovery and characterisation of the human multidomain inhibitor LEKTI (lympho-epithelial Kazal-type-related inhibitor, encoded by hspink5), several new members of the Kazal-type inhibitor family have been identified. Here we describe expression and regulation of murine SPINK12, a potential orthologue of human LEKTI2. Its expression was analysed by RT-PCR and immunohistochemistry revealing organ-specific pattern with high level of expression in the epidermis and several epithelia including the stomach, kidney and uterus. In addition, mSPINK12 expression in the epidermis of skin at footpads, where stratification is markedly pronounced, was several folds higher than in the abdominal epidermis. mSPINK12 mRNA levels were not affected by any cytokines tested while treatment of primary murine keratinocytes with the combination of calcium and sorbitol resulted in a strong increase in its mRNA. It appears that mspink12 is especially expressed in the epidermal areas with thick skin and that its regulation generally responds to differentiation signals. mrSPINK12 shows an inhibitory activity against murine keratinocyte-derived trypsin-like proteolytic activity, thus, the protein does appear orthologous to human LEKTI2 and may play an role in the regulation of epithelial cell functions.


Asunto(s)
Proteínas Inhibidoras de Proteinasas Secretoras/genética , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo , Piel/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Células Cultivadas , ADN Complementario/genética , Femenino , Regulación de la Expresión Génica , Humanos , Inmunohistoquímica , Masculino , Ratones , Ratones Endogámicos C57BL , Datos de Secuencia Molecular , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Inhibidores de Serinpeptidasas Tipo Kazal , Especificidad de la Especie
19.
J Microbiol Biotechnol ; 20(8): 1189-91, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20798580

RESUMEN

In an ongoing investigation of compounds from natural products that exhibit anti-aging properties, hydroxyhibiscone A (1), a new furanosesquiterpenoid, together with hibiscone D (2), was isolated from the root bark of Hibiscus syriacus. Utilizing UV, IR, NMR, and MS spectroscopic analyses, these chemical structures were revealed. Compounds 1 and 2 were found to possess significant anti-aging properties on the human neutrophil elastase (HNE) assay, exhibiting HNE inhibitory activities with IC50 values of 5.2 and 4.6 micronM, respectively.


Asunto(s)
Hibiscus/química , Elastasa de Leucocito/antagonistas & inhibidores , Extractos Vegetales/farmacología , Proteínas Inhibidoras de Proteinasas Secretoras/farmacología , Hibiscus/metabolismo , Humanos , Elastasa de Leucocito/análisis , Elastasa de Leucocito/metabolismo , Estructura Molecular , Extractos Vegetales/química , Extractos Vegetales/metabolismo , Proteínas Inhibidoras de Proteinasas Secretoras/química , Proteínas Inhibidoras de Proteinasas Secretoras/metabolismo
20.
Eur J Pharmacol ; 641(2-3): 220-5, 2010 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-20542026

RESUMEN

The present study was designed to examine the combined effects of a synthetic protease inhibitor, gabexate mesilate, with a specific neutrophil elastase inhibitor, sivelestat sodium, on acid-induced lung injury. Adult male Sprague-Dawley rats weighing 300-350 g were anaesthetised intraperitoneally with pentobarbitone sodium and the right jugular vein was cannulated. Following tracheostomy, rats were ventilated mechanically and underwent intratracheal instillation of hydrochloric acid (HCl, 0.1N 1.5 ml/kg) or normal saline. Gabexate mesilate (10mg/kg, i.p.) and/or sivelestat sodium (10mg/kg/h, i.v.) were administered 30 min before HCl instillation. Bronchoalveolar lavage fluid samples were obtained 5h after HCl instillation. In bronchoalveolar lavage fluid, the HCl-induced increases in total nucleated cell counts, neutrophil counts, optical density at 412 nm as an index of pulmonary haemorrhage, concentrations of albumin and cytokine-induced neutrophil chemoattractant (CINC) were significantly attenuated by either gabexate mesilate or sivelestat sodium treatment. Gabexate mesilate or sivelestat sodium treatment also significantly attenuated the wet to dry weight ratio induced by HCl. However, combined treatment with both gabexate mesilate and sivelestat sodium did not show additive effects on HCl-induced lung injury, compared with single treatments. These findings suggested that gabexate mesilate and sivelestat sodium each exhibited protective effects on acid-induced lung injury, but that synergistic effects of both agents are limited in this acid-induced lung injury model.


Asunto(s)
Gabexato/administración & dosificación , Glicina/análogos & derivados , Lesión Pulmonar/tratamiento farmacológico , Inhibidores de Proteasas/administración & dosificación , Proteínas Inhibidoras de Proteinasas Secretoras/uso terapéutico , Sulfonamidas/administración & dosificación , Animales , Líquido del Lavado Bronquioalveolar/citología , Evaluación Preclínica de Medicamentos , Sinergismo Farmacológico , Quimioterapia Combinada , Gabexato/efectos adversos , Glicina/administración & dosificación , Ácido Clorhídrico , Recuento de Leucocitos , Lesión Pulmonar/inducido químicamente , Masculino , Neutrófilos/efectos de los fármacos , Inhibidores de Proteasas/efectos adversos , Proteínas Inhibidoras de Proteinasas Secretoras/administración & dosificación , Distribución Aleatoria , Ratas , Ratas Sprague-Dawley , Sodio/efectos adversos , Sodio/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA